Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ: EWTX ) with a Neutral and raises the price target from $32 to $36.